What it is
Fibromyalgia is a form of nociplastic pain: the nervous system amplifies pain signals (central sensitization). Common symptoms are widespread aching, tenderness, fatigue, unrefreshing sleep, brain fog, headaches and irritable bowel symptoms. It often overlaps with other pain conditions.
How it is diagnosed
There is no single test. Diagnosis rests on the pattern of widespread pain and related symptoms over at least three months, as defined in the 2016 American College of Rheumatology criteria. An exam and blood work rule out conditions that can look similar, such as thyroid disease, inflammatory arthritis or vitamin deficiencies.
How we approach it
Use the Function Method, and measure function first: sleep, activity tolerance and daily-life goals. The plan includes:
- a graded exercise program that starts low and builds (aerobic and strength)
- pacing
- sleep care
- referral for cognitive behavioral therapy when helpful
- a review of every medication
- targeted care for any overlapping pain generator: myofascial, joint or nerve pain
Opioids are generally not recommended for fibromyalgia.
Medicines
Four medicines are FDA-approved for fibromyalgia:
- pregabalin (Lyrica)
- duloxetine (Cymbalta)
- milnacipran (Savella)
- sublingual cyclobenzaprine (Tonmya, approved in August 2025)
Low-dose amitriptyline is used off-label. Low-dose naltrexone is also used off-label, and recent controlled trials have been mixed. Any prescribing is physician-supervised after assessment and never guaranteed.
Related treatments
From the Journal
Common
questions.
When to seek
care urgently.
Seek emergency care for new bladder or bowel dysfunction, rapidly worsening weakness or severe pain with loss of limb circulation. A hot swollen joint with fever or new, rapidly changing symptoms needs prompt medical evaluation.
Sources
- Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016.
- Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017.
- U.S. FDA approval of Tonmya (cyclobenzaprine HCl sublingual tablets), August 2025.
- NIAMS: Fibromyalgia.
This page is general information, not medical advice. Individual results vary. Medical Disclaimer